The VDR Paradox: Normal Blood Tests, Vitamin D Resistance

You had your 25-hydroxyvitamin D tested. The number came back within the sufficient range. Your clinician reviewed the result and found nothing actionable. And yet the fatigue, the recurring infections, the suboptimal bone density, and the slow recovery continue unchanged. This is not an unusual scenario. For a clinically significant subset of the population, the problem is not insufficient circulating vitamin D. The problem is that the receptor designed to use that vitamin D is not translating it into biological effect. Standard laboratory panels are structurally incapable of detecting this distinction.

The mechanism is called functional vitamin D resistance. It is mediated by Vitamin D Receptor (VDR) polymorphisms that alter receptor architecture, expression levels, or transcriptional efficiency. Understanding it requires separating two concepts that clinical practice routinely conflates: vitamin D status in the bloodstream and vitamin D activity at the cellular level.

What the Serum 25(OH)D Test Actually Measures

The standard vitamin D blood test measures 25-hydroxyvitamin D, the storage form produced in the liver after hepatic 25-hydroxylation of vitamin D from sunlight or supplements. 25(OH)D is the most abundant circulating form of vitamin D and has a half-life of approximately 2 to 3 weeks, which makes it a practical and reproducible indicator of vitamin D nutritional status over time.

What it measures, precisely, is the concentration of substrate available in the bloodstream. A result of 50 ng/mL confirms that adequate 25(OH)D is circulating. It provides no information about the rate at which that substrate is being converted to calcitriol (1,25(OH)2D3) in target tissues. It provides no information about whether calcitriol is binding to a structurally competent VDR. And it provides no information about whether the VDR-calcitriol complex is activating downstream gene transcription at a level sufficient to produce the biological effects the body requires.

Interpreting serum 25(OH)D as a complete measure of vitamin D functional status is analogous to measuring the fuel level in a car's tank and concluding the engine is running at full capacity. The fuel supply is one variable in a multi-step process. The condition of the engine determines what that fuel actually produces.

The Concept of Functional Vitamin D Resistance

Functional vitamin D resistance describes a state in which circulating vitamin D levels appear adequate by conventional clinical criteria, but cellular responsiveness to vitamin D signaling is measurably impaired. The term "functional resistance" is chosen deliberately to parallel insulin resistance, a better-known clinical concept that operates by an analogous mechanism.

A person with insulin resistance can have normal or elevated insulin levels in their bloodstream. Their cells simply do not respond to that insulin with the appropriate intracellular signaling cascade. In VDR-mediated vitamin D resistance, the circulating substrate (25(OH)D, and the calcitriol derived from it) may be present in adequate concentrations, while the receptor that should translate that signal into gene expression is operating below functional threshold.

In both cases, the biomarker that standard clinical testing measures (serum insulin or serum 25(OH)D) can appear entirely unremarkable while the patient experiences the clinical consequences of the underlying cellular dysfunction.

How VDR Polymorphisms Create Cellular Resistance

The four most studied VDR variants, FokI (rs10735810), BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236), create functional resistance through distinct, mechanistically specific pathways. Each impairs a different aspect of the VDR's signal transduction function.

FokI: Reduced Receptor Potency

The FokI variant is located at the translation start site of the VDR gene (exon 2). It determines the length of the VDR protein produced: the common "F" allele produces a shorter protein that interacts more efficiently with the TFIIB component of the basal transcription machinery, while the "f" allele produces a longer protein with measurably weaker interaction efficiency. Cell culture studies have demonstrated that the ff genotype requires calcitriol concentrations up to three times higher than the FF genotype to achieve equivalent gene activation. The receptor is less potent: adequate substrate produces less response.

BsmI: Reduced Receptor Expression

BsmI is located in intron 8, near the 3' end of the VDR gene. The variant affects VDR mRNA stability, altering the rate at which VDR transcripts are degraded after synthesis. Reduced mRNA stability means fewer VDR protein molecules are produced per cell, lowering the total density of functional receptors available to bind calcitriol. Rather than reducing the potency of individual receptors, this variant reduces the ceiling of total receptor capacity, effectively limiting how much calcitriol signal can be processed per unit time.

ApaI and TaqI: Tissue-Specific Binding and Transcription Deficits

ApaI and TaqI are located in the 3' region and are in strong linkage disequilibrium with BsmI, meaning they are frequently inherited together as a haplotype block. ApaI is associated with reduced receptor binding affinity in bone and immune cell contexts. TaqI directly influences the transcriptional output of calcium transport genes, including calbindin-D9K and TRPV6, which are critical mediators of intestinal calcium absorption. Individuals carrying certain TaqI variants show measurably reduced calcium absorption efficiency even when calcitriol levels are adequate, a direct demonstration of downstream functional resistance in a well-studied target tissue.

Why Standard Testing Consistently Misses This

The reason serum 25(OH)D testing fails to detect functional resistance is structural, not a limitation that can be corrected by ordering a more sensitive version of the same test. The assay measures circulating substrate. There is no widely available clinical test that quantifies VDR transcriptional activity in target tissues directly. Doing so would require tissue biopsies followed by gene expression profiling, a level of invasiveness and analytical complexity that is not practical in routine clinical settings.

The practical consequence is that clinicians who use 25(OH)D as their primary, or sole, indicator of vitamin D sufficiency will reliably find nothing to address in patients whose impairment is receptor-level. The test looks normal because the thing it measures is normal. The biological dysfunction occurs one layer downstream, in a process the test is not designed to evaluate.

Clinical Patterns That Suggest Functional Resistance

Because standard panels do not capture this mechanism, clinicians and patients often need to interpret a broader pattern of evidence. Several presentations recur frequently enough among individuals with VDR polymorphisms to warrant consideration:

• Serum 25(OH)D levels that are difficult to maintain above 50 ng/mL without doses exceeding 4,000 to 5,000 IU per day
• Persistent bone density concerns, or a declining trajectory on DEXA scans, despite calcium and vitamin D supplementation within guideline ranges
• Repeated upper respiratory infections, particularly in winter, disproportionate to the person's overall health and hygiene practices
• Chronic fatigue and mood instability that do not improve despite achieving serum 25(OH)D levels clinicians consider sufficient
• Poor wound healing or prolonged recovery from physical training
• A family history pattern of osteoporosis, autoimmune conditions, or immune dysregulation in first-degree relatives, consistent with heritable receptor variance

None of these presentations are diagnostic of VDR polymorphisms on their own. They are signals that warrant deeper investigation, specifically at the genetic level, rather than reflexive escalation of vitamin D supplementation.

Bridging the Gap: From Substrate Status to Receptor Function

The diagnostic gap between a normal blood test and abnormal biological experience can be addressed at two levels. The first is genetic: determining which VDR variants are present provides a mechanistic framework for interpreting serum results in context. A 25(OH)D level of 50 ng/mL carries different clinical implications for a person with a homozygous FokI "ff" genotype, where receptor potency is substantially reduced, than for a person with the optimal "FF" genotype. The number is the same; the biological meaning is not.

The second level is protocol adjustment. For individuals with confirmed significant VDR polymorphisms, targeting serum 25(OH)D at the higher end of the reference range (60 to 80 ng/mL rather than 30 to 50 ng/mL) may be worth discussing with a healthcare provider, on the mechanistic rationale that increased substrate availability can partially compensate for reduced receptor efficiency. Cofactor optimization, particularly addressing magnesium and zinc status, can recover additional functional capacity that supplementing vitamin D alone leaves unaddressed.

The precision lies in knowing which variants you carry, because the specific receptor deficits determine which interventions are most likely to produce a meaningful biological response.